Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Beam Therapeutics Inc.BEAM · Entity 4227 | Director · CEO | June 29, 2026 | July 01, 2026 |
| Verve Therapeutics, Inc.VERV · Entity 11259 | Director | June 09, 2022 | June 13, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Beam Therapeutics Inc.
Report date June 29, 2026 · Filed July 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,047,205 |
Ending reported balance
After 2026-06-30 transaction · row 7
7 source rows · reconciled sequenceRow 1 · 2026-06-29 · Exercise / conversion · Acquired 18,663 · Balance 1,065,868 F1: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. Row 2 · 2026-06-29 · Exercise / conversion · Acquired 6,337 · Balance 1,072,205 F1: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. Row 3 · 2026-06-29 · Sale · Disposed 13,421 · Balance 1,058,784 F1: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $34.55 to $35.50, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Row 4 · 2026-06-29 · Sale · Disposed 11,579 · Balance 1,047,205 F1: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $35.60 to $36.18, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Row 5 · 2026-06-30 · Exercise / conversion · Acquired 25,000 · Balance 1,072,205 F1: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. Row 6 · 2026-06-30 · Sale · Disposed 23,100 · Balance 1,049,105 F1: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $33.80 to $34.71, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Row 7 · 2026-06-30 · Sale · Disposed 1,900 · Balance 1,047,205 F1: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $34.83 to $34.85, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.67 · Expires 2028-05-08 | Direct | 9 |
Reported balance
After 2026-06-29 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-06-29 · Exercise / conversion · Disposed 18,663 · Balance 9 F1: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. F6: On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,396 shares upon the achievement of a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 99,336 shares. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.03 · Expires 2028-07-13 | Direct | 230,804 |
Reported balance
After 2026-06-29 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-06-29 · Exercise / conversion · Disposed 6,337 · Balance 230,804 F1: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. F7: On July 13, 2018, the Reporting Person was granted an option to purchase 539,645 shares of common stock, which vested as to 25% of the underlying shares on January 8, 2019 and in 36 equal monthly installments thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.03 · Expires 2028-07-13 | Direct | 205,804 |
Reported balance
After 2026-06-30 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-06-30 · Exercise / conversion · Disposed 25,000 · Balance 205,804 F1: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. F7: On July 13, 2018, the Reporting Person was granted an option to purchase 539,645 shares of common stock, which vested as to 25% of the underlying shares on January 8, 2019 and in 36 equal monthly installments thereafter. |
| Common StockSEC Table I · non-derivative | IndirectBy John M. Evans, III 2018 Irrevocable Trust | 103,000 |
Reported balance
Holding disclosure · report date 2026-06-29 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 103,000 |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $34.55 to $35.50, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $35.60 to $36.18, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $33.80 to $34.71, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $34.83 to $34.85, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F6: On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,396 shares upon the achievement of a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 99,336 shares.
F7: On July 13, 2018, the Reporting Person was granted an option to purchase 539,645 shares of common stock, which vested as to 25% of the underlying shares on January 8, 2019 and in 36 equal monthly installments thereafter.
Verve Therapeutics, Inc.
Report date June 09, 2022 · Filed June 13, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.04 · Expires 2032-06-08 | Direct | 15,500 |
Reported balance
After 2022-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-09 · Grant · Acquired 15,500 · Balance 15,500 F1: This stock option was issued pursuant to the 2021 Stock Incentive Plan of Verve Therapeutics, Inc. in accordance with its director compensation program. The vesting commencement date (the "Vesting Commencement Date") of the options is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or immediately prior to the first annual meeting of stockholders occurring after the grant date, in each case subject to the Reporting Person's continued service as a director. |
Filing footnotes · ownership attribution and instrument terms
F1: This stock option was issued pursuant to the 2021 Stock Incentive Plan of Verve Therapeutics, Inc. in accordance with its director compensation program. The vesting commencement date (the "Vesting Commencement Date") of the options is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or immediately prior to the first annual meeting of stockholders occurring after the grant date, in each case subject to the Reporting Person's continued service as a director.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 31, 2024 Filed Feb 2, 2024 21:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 60,000 | $25.33 | $1,519,800.00 |
DisclosureSEC source: 0000950170-24-010477 · ownership.xml · nonDerivative · entry 1 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,058,262 F1 · kind: These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $24.93 to $25.92 inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 283 shares acquired by the Reporting Person under the Beam Therapeutics Inc. Amended and Restated 2019 Employee Stock Purchase Plan on September 30, 2023. Read SEC document |
| April 04, 2023 Filed Apr 6, 2023 00:30 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 6,493 | $29.09 | $188,904.10 |
DisclosureSEC source: 0000899243-23-010819 · doc4.xml · nonDerivative · entry 2 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,117,979 F1 · kind: These shares of common stock were sold pursuant to a a Rule 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $28.81 to $29.10, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 03, 2023 Filed Apr 6, 2023 00:30 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 5,161 | $30.31 | $156,429.91 |
DisclosureSEC source: 0000899243-23-010819 · doc4.xml · nonDerivative · entry 1 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,124,472 F1 · kind: These shares of common stock were sold pursuant to a a Rule 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023. F2 · balance_after: Includes 480 shares acquired by the Reporting Person under the Beam Therapeutics Inc. Amended and Restated 2019 Employee Stock Purchase Plan on March 31, 2023. Read SEC document |
| March 31, 2023 Filed Mar 31, 2023 23:48 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,850 | $0.00 Strike: $7.22 | $0.00 |
DisclosureSEC source: 0000899243-23-010137 · doc4.xml · derivative · entry 6 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 196,904 Underlying: Common Stock · 13,850 shares Expires 2029-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This stock option vests as to 25% on the first anniversary of the vesting commencement date, October 1, 2019, and at a rate of 2.78% each month thereafter until the option is fully vested. .. Read SEC document |
| March 31, 2023 Filed Mar 31, 2023 23:48 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionCommon Stock | 13,850 | $7.22 | $99,997.00 |
DisclosureSEC source: 0000899243-23-010137 · doc4.xml · nonDerivative · entry 3 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,129,153 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2023 Filed Mar 31, 2023 23:48 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantCommon Stock | 56,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-010137 · doc4.xml · nonDerivative · entry 2 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,115,303 F3 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under BEAM's 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the BEAM's common stock. The RSUs vest in four substantially equal annual installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date. Read SEC document |
| March 06, 2023 Filed Mar 31, 2023 23:48 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | OtherCommon Stock | 225 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-010137 · doc4.xml · nonDerivative · entry 1 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,059,053 F1 · kind: Distribution of Beam Therapeutics Inc. ("BEAM") common stock held by ARCH Venture Fund IX, L.P. to its partners for no consideration. F2 · balance_after: Includes 308 shares and acquired by the Reporting Person under the BEAM Amended and Restated 2019 Employee Stock Purchase Plan on September 30, 2022. Read SEC document |
| January 31, 2023 Filed Mar 31, 2023 23:48 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantStock Option (Right to Buy) · Derivative | 112,500 | $0.00 Strike: $43.45 | $0.00 |
DisclosureSEC source: 0000899243-23-010137 · doc4.xml · derivative · entry 5 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,500 Underlying: Common Stock · 112,500 shares Expires 2033-01-31 F4 · derivative.exercise_date: This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the reporting person's continued service with BEAM through each vesting date. Read SEC document |
| October 31, 2022 Filed Nov 2, 2022 20:30 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 2,188 | $47.91 | $104,836.49 |
DisclosureSEC source: 0000899243-22-034759 · doc4.xml · nonDerivative · entry 8 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust Disclosed balance after: 103,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $47.57 to $48.40, inclusive. Read SEC document |
| October 31, 2022 Filed Nov 2, 2022 20:30 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 8,235 | $46.91 | $386,339.26 |
DisclosureSEC source: 0000899243-22-034759 · doc4.xml · nonDerivative · entry 7 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust Disclosed balance after: 105,188 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $46.57 to $47.555, inclusive. Read SEC document |
| October 31, 2022 Filed Nov 2, 2022 20:30 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 4,569 | $46.19 | $211,033.89 |
DisclosureSEC source: 0000899243-22-034759 · doc4.xml · nonDerivative · entry 6 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust Disclosed balance after: 113,423 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $45.57 to $46.56, inclusive. Read SEC document |
| October 31, 2022 Filed Nov 2, 2022 20:30 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 5,008 | $44.93 | $224,993.41 |
DisclosureSEC source: 0000899243-22-034759 · doc4.xml · nonDerivative · entry 5 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust Disclosed balance after: 117,992 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $44.48 to $45.445, inclusive. Read SEC document |
| October 31, 2022 Filed Nov 2, 2022 20:30 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 2,909 | $47.89 | $139,324.81 |
DisclosureSEC source: 0000899243-22-034759 · doc4.xml · nonDerivative · entry 4 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,058,520 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $47.68 to $48.17, inclusive. Read SEC document |
| October 31, 2022 Filed Nov 2, 2022 20:30 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 11,756 | $46.88 | $551,136.56 |
DisclosureSEC source: 0000899243-22-034759 · doc4.xml · nonDerivative · entry 3 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,061,429 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $46.57 to $47.52, inclusive. Read SEC document |
| October 31, 2022 Filed Nov 2, 2022 20:30 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 7,768 | $46.19 | $358,819.46 |
DisclosureSEC source: 0000899243-22-034759 · doc4.xml · nonDerivative · entry 2 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,073,185 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $45.57 to $46.56, inclusive. Read SEC document |
| October 31, 2022 Filed Nov 2, 2022 20:30 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 7,567 | $44.92 | $339,944.45 |
DisclosureSEC source: 0000899243-22-034759 · doc4.xml · nonDerivative · entry 1 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,080,953 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $44.48 to $45.445, inclusive. Read SEC document |
| July 28, 2022 Filed Jul 29, 2022 20:06 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 2,247 | $67.82 | $152,383.23 |
DisclosureSEC source: 0000899243-22-027077 · doc4.xml · nonDerivative · entry 9 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust Disclosed balance after: 123,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $67.72 to $68.49, inclusive. Read SEC document |
| July 28, 2022 Filed Jul 29, 2022 20:06 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 201 | $66.61 | $13,388.51 |
DisclosureSEC source: 0000899243-22-027077 · doc4.xml · nonDerivative · entry 8 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust Disclosed balance after: 125,247 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $66.50 to $66.61, inclusive. Read SEC document |
| July 28, 2022 Filed Jul 29, 2022 20:06 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 10,599 | $65.92 | $698,673.36 |
DisclosureSEC source: 0000899243-22-027077 · doc4.xml · nonDerivative · entry 7 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust Disclosed balance after: 125,448 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $65.46 to $66.45, inclusive. Read SEC document |
| July 28, 2022 Filed Jul 29, 2022 20:06 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 6,953 | $64.88 | $451,113.42 |
DisclosureSEC source: 0000899243-22-027077 · doc4.xml · nonDerivative · entry 6 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust Disclosed balance after: 136,047 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $64.43 to $65.38, inclusive. Read SEC document |
| July 28, 2022 Filed Jul 29, 2022 20:06 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 173 | $68.49 | $11,848.77 |
DisclosureSEC source: 0000899243-22-027077 · doc4.xml · nonDerivative · entry 5 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,088,520 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 28, 2022 Filed Jul 29, 2022 20:06 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 2,848 | $67.80 | $193,093.26 |
DisclosureSEC source: 0000899243-22-027077 · doc4.xml · nonDerivative · entry 4 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,088,693 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $67.45 to $67.87, inclusive. Read SEC document |
| July 28, 2022 Filed Jul 29, 2022 20:06 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 1,562 | $66.74 | $104,255.38 |
DisclosureSEC source: 0000899243-22-027077 · doc4.xml · nonDerivative · entry 3 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,091,541 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $66.44 to $67.37, inclusive. Read SEC document |
| July 28, 2022 Filed Jul 29, 2022 20:06 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 15,236 | $65.82 | $1,002,895.99 |
DisclosureSEC source: 0000899243-22-027077 · doc4.xml · nonDerivative · entry 2 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,093,103 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $65.43 to $66.34, inclusive. Read SEC document |
| July 28, 2022 Filed Jul 29, 2022 20:06 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 10,181 | $64.87 | $660,429.25 |
DisclosureSEC source: 0000899243-22-027077 · doc4.xml · nonDerivative · entry 1 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,108,339 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $64.43 to $65.42, inclusive. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 17:00 UTC | Verve Therapeutics, Inc. VERV · Entity 11259 | GrantStock Option (right to buy) · Derivative | 15,500 | $0.00 Strike: $14.04 | $0.00 |
DisclosureSEC source: 0001209191-22-036366 · doc4.xml · derivative · entry 1 Evans John M. · CIK 0001786304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,500 Underlying: Common Stock · 15,500 shares Expires 2032-06-08 F1 · derivative.exercise_date: This stock option was issued pursuant to the 2021 Stock Incentive Plan of Verve Therapeutics, Inc. in accordance with its director compensation program. The vesting commencement date (the "Vesting Commencement Date") of the options is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or immediately prior to the first annual meeting of stockholders occurring after the grant date, in each case subject to the Reporting Person's continued service as a director. Read SEC document |
| April 28, 2022 Filed May 2, 2022 22:51 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionStock Option (Right to Buy) · Derivative | 47,204 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0000899243-22-016164 · doc4.xml · derivative · entry 14 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,141 Underlying: Common Stock · 47,204 shares Expires 2028-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F13 · derivative.exercise_date: The option vests as to 25% on the first anniversary of the of the vesting commencement date, October 1, 2019, and at a rate of 2.78% each month thereafter until the option is fully vested. Read SEC document |
| April 28, 2022 Filed May 2, 2022 22:51 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,246 | $0.00 Strike: $7.22 | $0.00 |
DisclosureSEC source: 0000899243-22-016164 · doc4.xml · derivative · entry 13 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,754 Underlying: Common Stock · 12,246 shares Expires 2029-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: The option vests as to 25% on the first anniversary of the of the vesting commencement date, January 8, 2018, and at a rate of 2.78% each month thereafter until the option is fully vested. Read SEC document |
| April 28, 2022 Filed May 2, 2022 22:51 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 357 | $40.88 | $14,594.16 |
DisclosureSEC source: 0000899243-22-016164 · doc4.xml · nonDerivative · entry 12 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust Disclosed balance after: 143,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $40.70 to $40.96, inclusive. Read SEC document |
| April 28, 2022 Filed May 2, 2022 22:51 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 2,348 | $39.73 | $93,286.04 |
DisclosureSEC source: 0000899243-22-016164 · doc4.xml · nonDerivative · entry 11 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust Disclosed balance after: 143,357 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $39.51 to $40.32, inclusive. Read SEC document |
| April 28, 2022 Filed May 2, 2022 22:51 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 3,100 | $38.75 | $120,125.00 |
DisclosureSEC source: 0000899243-22-016164 · doc4.xml · nonDerivative · entry 10 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust Disclosed balance after: 145,705 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $38.405 to $39.261, inclusive. Read SEC document |
| April 28, 2022 Filed May 2, 2022 22:51 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 7,745 | $37.84 | $293,070.80 |
DisclosureSEC source: 0000899243-22-016164 · doc4.xml · nonDerivative · entry 9 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust Disclosed balance after: 148,805 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $37.38 to $38.37, inclusive. Read SEC document |
| April 28, 2022 Filed May 2, 2022 22:51 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 6,450 | $36.98 | $238,521.00 |
DisclosureSEC source: 0000899243-22-016164 · doc4.xml · nonDerivative · entry 8 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust Disclosed balance after: 156,550 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $36.36 to $37.34, inclusive. Read SEC document |
| April 28, 2022 Filed May 2, 2022 22:51 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 1,100 | $40.73 | $44,803.00 |
DisclosureSEC source: 0000899243-22-016164 · doc4.xml · nonDerivative · entry 7 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,118,520 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $40.08 to $40.80, inclusive. Read SEC document |
| April 28, 2022 Filed May 2, 2022 22:51 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 4,503 | $39.49 | $177,823.47 |
DisclosureSEC source: 0000899243-22-016164 · doc4.xml · nonDerivative · entry 6 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,119,620 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $39.21 to $39.88, inclusive. Read SEC document |
| April 28, 2022 Filed May 2, 2022 22:51 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 6,842 | $38.32 | $262,185.44 |
DisclosureSEC source: 0000899243-22-016164 · doc4.xml · nonDerivative · entry 5 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,124,123 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $38.09 to $38.67, inclusive. Read SEC document |
| April 28, 2022 Filed May 2, 2022 22:51 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 13,655 | $37.48 | $511,789.40 |
DisclosureSEC source: 0000899243-22-016164 · doc4.xml · nonDerivative · entry 4 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,130,965 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $37.06 to $37.86, inclusive. Read SEC document |
| April 28, 2022 Filed May 2, 2022 22:51 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 3,900 | $36.59 | $142,701.00 |
DisclosureSEC source: 0000899243-22-016164 · doc4.xml · nonDerivative · entry 3 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,144,620 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $36.36 to $36.97, inclusive. Read SEC document |
| April 28, 2022 Filed May 2, 2022 22:51 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionCommon Stock | 47,204 | $1.03 | $48,620.12 |
DisclosureSEC source: 0000899243-22-016164 · doc4.xml · nonDerivative · entry 2 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,148,520 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 28, 2022 Filed May 2, 2022 22:51 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionCommon Stock | 12,246 | $7.22 | $88,416.12 |
DisclosureSEC source: 0000899243-22-016164 · doc4.xml · nonDerivative · entry 1 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,101,316 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2022 Filed Apr 5, 2022 00:27 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 6,261 | $59.11 | $370,087.71 |
DisclosureSEC source: 0000899243-22-013487 · doc4.xml · nonDerivative · entry 2 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,089,070 F3 · shares: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain RSUs. Read SEC document |
| March 31, 2022 Filed Apr 5, 2022 00:27 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantCommon Stock | 56,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-013487 · doc4.xml · nonDerivative · entry 1 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,095,331 F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under the Issuer's 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four substantially equal annual installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with the Company through each vesting date. F2 · balance_after: Includes 256 shares acquired under the Issuer's employee stock purchase plan on March 31, 2022. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 23:00 UTC Amendment | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantStock Option (Right to Buy) · Derivative | 112,500 | $0.00 Strike: $69.21 | $0.00 |
DisclosureSEC source: 0000899243-22-004197 · doc4a.xml · derivative · entry 18 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,500 Underlying: Common Stock · 112,500 shares Expires 2032-01-31 F16 · derivative.exercise_date: The option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the reporting person's continued service with BEAM through each vesting date. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 23:00 UTC Amendment | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0000899243-22-004197 · doc4a.xml · derivative · entry 17 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,345 Underlying: Common Stock · 100,000 shares Expires 2028-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F15 · derivative.exercise_date: The option vests as to 25% on the first anniversary of the of the vesting commencement date, January 8, 2018, and at a rate of 2.78% each month thereafter until the option is fully vested. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 23:00 UTC Amendment | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 2,672 | $68.16 | $182,123.52 |
DisclosureSEC source: 0000899243-22-004197 · doc4a.xml · nonDerivative · entry 15 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust Disclosed balance after: 163,000 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The reporting person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $68.00 to $68.60, inclusive. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 23:00 UTC Amendment | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 9,408 | $67.43 | $634,381.44 |
DisclosureSEC source: 0000899243-22-004197 · doc4a.xml · nonDerivative · entry 14 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust Disclosed balance after: 165,672 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The reporting person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $67.00 to $67.99, inclusive. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 23:00 UTC Amendment | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 4,105 | $66.48 | $272,900.40 |
DisclosureSEC source: 0000899243-22-004197 · doc4a.xml · nonDerivative · entry 13 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust Disclosed balance after: 175,080 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The reporting person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $66.00 to $66.94, inclusive. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 23:00 UTC Amendment | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 1,900 | $65.55 | $124,545.00 |
DisclosureSEC source: 0000899243-22-004197 · doc4a.xml · nonDerivative · entry 12 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust Disclosed balance after: 179,185 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The reporting person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $65.20 to $65.99, inclusive. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 23:00 UTC Amendment | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 1,615 | $64.46 | $104,102.90 |
DisclosureSEC source: 0000899243-22-004197 · doc4a.xml · nonDerivative · entry 11 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust Disclosed balance after: 181,085 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The reporting person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $64.17 to $64.50, inclusive. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 23:00 UTC Amendment | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 300 | $63.45 | $19,035.00 |
DisclosureSEC source: 0000899243-22-004197 · doc4a.xml · nonDerivative · entry 10 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust Disclosed balance after: 182,700 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The reporting person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $63.26 to $63.58, inclusive. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.